Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. - Wikidata - wikimedia - TriplyDB

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

http://www.wikidata.org/entity/Q53387315

about

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome The RNA Splicing Response to DNA Damage Myeloid malignancies: mutations, models and management U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.Epigenetics in Cancer: A Hematological Perspective Refractory anemia with ring sideroblasts and RARS with thrombocytosis Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.PRPF8 defects cause missplicing in myeloid malignancies.DNMT3A in haematological malignancies.Detection of SRSF2-P95 mutation by high-resolution melting curve analysis and its effect on prognosis in myelodysplastic syndrome.Limiting of the innate immune response by SF3A-dependent control of MyD88 alternative mRNA splicing.Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing Regulation of toll-like receptor signaling by the SF3a mRNA splicing complex.Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.Clinical and biological implications of driver mutations in myelodysplastic syndromes.Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.The genetic basis of myelodysplasia and its clinical relevance RNA splicing factors as oncoproteins and tumour suppressors.Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.Aberrant splicing in maize rough endosperm3 reveals a conserved role for U12 splicing in eukaryotic multicellular development.Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.Myelodysplastic syndrome hematopoietic stem cell.Splicing factor mutations in myelodysplasia.Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.

P2860

Q24632949-11E11A4C-4A67-48E3-A0AB-4E93841B7BC9 Q26777046-1BBA0AE8-C300-43B0-9DA1-58316027CC1C Q27000577-C9DF6AA6-26A9-4FCF-A763-9D83B5C43102 Q27851921-5717C045-7822-4404-945E-CEE2F6BAE313 Q27852437-D11F8691-E396-4F51-8741-46646029B0A7 Q28077082-B782ECB6-5AFE-4AD3-BC11-8118DC50F6D6 Q28083238-8CADF1E8-3C16-43D6-A81B-68106B4BE485 Q30235355-71979E3F-ACEE-4900-B6C4-4349E1606CA3 Q30883788-84AEAF9F-3A4D-417D-91BA-DF41B6A08E2E Q33746465-E1295175-68C9-4079-BAD3-DE5C7C23897E Q34010735-807EAA2A-8708-4A1F-A28F-6964750C8925 Q34429362-B29EAC8E-897C-4842-8AF0-E76B5408336E Q34463554-AAF62918-47E1-4027-946C-33C481D9886C Q34776733-9D644F95-5EA2-4CF8-B67D-B2EEA84105A1 Q35034303-63B75016-D95A-46D8-B1BB-56EA25670A09 Q35148150-ECCC3EBF-61E0-49D4-8D2A-F7B999899787 Q35348356-30C1C457-6306-4A2D-9B7C-27070C4A91CA Q35556982-E98425E5-AA0E-411D-A7E5-CA589F57B3C9 Q35604082-24C736D5-9835-4442-9EF7-C1ED6A68DDA6 Q35675958-2B98C654-2686-4294-AD8F-41C6AC0806E8 Q35713371-A576FFB9-F916-4538-9B68-019885541BB8 Q36110604-A4093C6C-3E16-4988-9E52-6AE80F47CCB6 Q36579162-F2967A3A-5D95-4C8B-8E80-6D28765463B7 Q36936451-5C1178E3-DDE7-4B3A-BBFC-0FAEAD9DBCC4 Q36962514-35D57DF1-D6DA-46FD-8BCF-EFF5BEC5CBB2 Q36967122-6E6AEAF9-567D-48C8-85A9-48AC9E8CA0C7 Q37075929-DC1DC899-4047-4066-B347-DA6FC3946432 Q37078001-73CCF42E-191E-4237-B8C3-E2FC6B063218 Q37327426-088DEBEA-7D76-458C-BA41-C307B103FBAE Q37334716-00B37206-72AD-466C-8277-0C097BB24AB2 Q37377901-A84F2421-6126-42AF-B959-3DDA6F7AAF49 Q37390236-7D645A54-BF63-4398-A664-FC073AC93F4B Q37391660-BEE161C0-419F-4192-8A3C-BEFC4089B42D Q37581442-50B37C0D-7FDB-42B0-B82E-05DF16935EC2 Q37711600-55297F68-D299-4A68-A719-4EC3DCCC68A1 Q37995804-27A2A197-7880-48B0-9A76-71C0FBDD7F8A Q38000919-DC33ACAE-EE76-493F-939A-1BAEE2344E9B Q38050694-7F9B346B-49BC-4BC0-ABA5-A43EF021949F Q38051189-CD2B4F35-A83B-48A4-82D5-2054BBBF6E78 Q38060535-32E61392-79EF-4BF4-B4A5-3E66ED841738

P2860

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

http://www.wikidata.org/entity/Q53387315

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Mutations affecting mRNA splic ...... in myelodysplastic syndromes.

@en

Mutations affecting mRNA splic ...... in myelodysplastic syndromes.

@nl

type

label

Mutations affecting mRNA splic ...... in myelodysplastic syndromes.

@en

Mutations affecting mRNA splic ...... in myelodysplastic syndromes.

@nl

prefLabel

Mutations affecting mRNA splic ...... in myelodysplastic syndromes.

@en

Mutations affecting mRNA splic ...... in myelodysplastic syndromes.

@nl

P1433

Q53387315-4DC9B650-99D9-4435-86B6-736659C837E4

P1476

Q53387315-0840BE30-8CF4-44DB-910E-D16D61CEC5DA

P2093

Q53387315-0CB75C5F-FE96-4AC9-BB98-E3C5973B674E

Q53387315-357FCF48-D6E7-4FD0-90D6-54F15392C0AC

Q53387315-429117C1-F630-4AAF-A140-2F972349EDD9

Q53387315-45963DC6-8DD4-4CCB-AEC3-9DF874AF5159

Q53387315-4B9C8225-B39C-4C8E-8983-ADA709B25923

Q53387315-5586DA0C-1285-4E52-B1EF-60A3B78D8FD0

Q53387315-58939BF9-2B6D-4CA6-8A33-58E1EFC3E706

Q53387315-5EFE7FDC-3BFB-4A6F-AA9C-30C27D5D6AAC

Q53387315-7B770D57-36DB-45FC-964E-C5BC400AD2E6

Q53387315-89952B89-A8A0-4489-A13A-70B95D78A13B

P304

Q53387315-6B031489-22F9-4AD7-9F6E-34ABE71FBFAA

P31

Q53387315-B267111F-2F5F-479B-A365-D492990FB1A3

P356

Q53387315-51075784-715A-4DEF-A18D-12ED5EFB3E5B

P407

Q53387315-F5706CC8-2A54-49FA-852B-D1CC25144573

P433

Q53387315-AEE57662-7312-475F-A7A9-37105CCD90D6

P478

Q53387315-AFF5166D-19FA-46DA-AD9C-444CC4575EF7

P50

Q53387315-178627D2-7A38-4C13-A2E9-9E6C523E5FB5

Q53387315-29242169-596C-4660-A3C7-EF4840388319

Q53387315-66335088-44FE-468D-9979-4BF6FA110244

Q53387315-773B7EE2-D1E2-40A3-9984-B972DFE32743

Q53387315-DB765126-E585-47AC-9659-467B90882E80

Q53387315-DDE18222-8C5A-45BF-8586-05104BDD75FD

Q53387315-DEBB8F40-92D4-44DF-95D9-50E6B4E35011

Q53387315-EC0A8332-F332-47F0-A29F-480F598D73E9

Q53387315-EC28C806-41A3-4613-A542-FF0AD2CAF156

P577

Q53387315-A0691ACD-4963-492E-87D3-85C4DDEFD017

P5875

Q53387315-34BF44F4-956D-44C0-8C93-A6B40D5C4BC7

P698

Q53387315-F1AFCB13-2A28-49E7-85C5-CD3D25100E77

P921

Q53387315-994BE427-1A39-4A0D-8DE1-4200080299ED

P356

BLOOD-2011-12-400994

P1433

P1476

Mutations affecting mRNA splic ...... e in myelodysplastic syndromes

@en

P2093

Agnes Guerci-Bresler

http://www.w3.org/2001/XMLSchema#string

Aline Renneville

http://www.w3.org/2001/XMLSchema#string

Aline Schmidt-Tanguy

http://www.w3.org/2001/XMLSchema#string

Aspasia Stamatoullas-Bastard

http://www.w3.org/2001/XMLSchema#string

Bohrane Slama

http://www.w3.org/2001/XMLSchema#string

Claire Hidalgo-Curtis

http://www.w3.org/2001/XMLSchema#string

François Dreyfus

http://www.w3.org/2001/XMLSchema#string

Frederik Damm

http://www.w3.org/2001/XMLSchema#string

Groupe Francophone des Myélodysplasies

http://www.w3.org/2001/XMLSchema#string

Laurianne Scourzic

http://www.w3.org/2001/XMLSchema#string

P304

3211-3218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-12-400994

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Claude Preudhomme

Michaela Fontenay

Lucile Couronné

Stéphane de Botton

Olivier Kosmider

Daniel Birnbaum

Olivier Bernard

P577

2012-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221841437

http://www.w3.org/2001/XMLSchema#string

P698

22343920

http://www.w3.org/2001/XMLSchema#string

P921